Vivos Therapeutics, Inc. Announces Resignation of Dave Singh as Member of Board of Directors
September 27, 2021 at 09:01 am EDT
Share
On September 22, 2021, Vivos Therapeutics, Inc. entered into a Sabbatical Agreement with Dr. G. Dave Singh (Dr. Singh), the Company’s founder, Chief Medical Officer and director. The Agreement serves as an amendment to that certain Amended and Restated Employment Agreement, dated October 9, 2020, between the Company and Dr. Singh (the Employment Agreement). Pursuant to the Agreement, Dr. Singh’s sabbatical will be for a period of twelve (12) months from September 1, 2021, during which time Dr. Singh’s benefits and compensation shall remain the same. Dr. Singh will retain his title as Chief Medical Officer during his sabbatical, but pursuant to the Agreement, he has resigned as a member of the company’s board of directors, effective September 22, 2021.
Vivos Therapeutics, Inc. is a medical technology company focused on developing and commercializing diagnostic and treatment methods for patients suffering from breathing and sleep issues arising from certain dentofacial abnormalities such as obstructive sleep apnea (OSA) and snoring in adults. The Company calls its solution The Vivos Method. The Vivos Method represents the first clinically effective nonsurgical, noninvasive and nonpharmaceutical solution for treating mild to severe OSA. The Vivos Method includes treatment regimens that employ the proprietary Complete Airway Repositioning and/or Expansion (CARE) appliance therapy and other modalities that alter the size, shape and position of the soft tissues that comprise a patient's upper airway and/or palate. The Vivos Method comprises various products and services, including Vivos CARE oral appliance therapy, Vivos oral appliances and therapies outside of CARE system, Vivos AireO2, and Vivos Airway Intelligence Service.
VIVOS THERAPEUTICS, INC. 
